Carla Torre1, José Guerreiro2, Patrícia Longo2, João Filipe Raposo3, Hubert Leufkens4, Ana Paula Martins5. 1. Centre for Health Evaluation & Research (CEFAR), National Association of Pharmacies, Lisboa, Portugal; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisboa, Portugal. Electronic address: carla.torre@campus.ul.pt. 2. Centre for Health Evaluation & Research (CEFAR), National Association of Pharmacies, Lisboa, Portugal. 3. Nova Medical School, New University of Lisbon, Lisboa, Portugal; Portuguese Diabetes Association (APDP), Lisboa, Portugal. 4. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. 5. Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisboa, Portugal; Faculty of Pharmacy, University of Lisbon, Lisboa, Portugal.
Abstract
AIMS: To assess baseline and change after 26-weeks in health-related quality of life (HRQoL) among adults with type 2 diabetes mellitus (T2DM) initiating one of the new glucose lowering drugs (GLD) in daily practice. METHODS: Inception cohort of patients who initiated one of dipeptidyl peptidase 4 inhibitors (DPP-4), glucagon-like peptide-1 analogues (GLP-1) or sodium-glucose cotransporter inhibitors (SGLT2) drugs. A baseline questionnaire collected socio-demographic and self-reported clinical data. HRQoL was assessed by the Euroqol-5D. Participants were divided into: (1) incident new users (INU) (who used for the first time one of the monitored GLD and had no current or prior experience with DPP-4/GLP-1/SGLT2) and (2) prevalent new users (PNU) (who had previously used at least one GLD of the monitored drug classes, but not the inception drug). Multivariate regression explored factors associated with a meaningful change in HRQoL. RESULTS: 1303 patients. Over 26weeks, a mean positive change in the EQ-5D scores, were observed. No differences between INU and PNU were found. Participants with worse health conditions (e.g. presence and number of chronic diseases, obese) at baseline were more likely to experience larger improvements in HRQoL. CONCLUSIONS: Over 26-weeks, T2DM patients starting with, or switching to new GLD maintained or modestly increased their HRQoL.
AIMS: To assess baseline and change after 26-weeks in health-related quality of life (HRQoL) among adults with type 2 diabetes mellitus (T2DM) initiating one of the new glucose lowering drugs (GLD) in daily practice. METHODS: Inception cohort of patients who initiated one of dipeptidyl peptidase 4 inhibitors (DPP-4), glucagon-like peptide-1 analogues (GLP-1) or sodium-glucose cotransporter inhibitors (SGLT2) drugs. A baseline questionnaire collected socio-demographic and self-reported clinical data. HRQoL was assessed by the Euroqol-5D. Participants were divided into: (1) incident new users (INU) (who used for the first time one of the monitored GLD and had no current or prior experience with DPP-4/GLP-1/SGLT2) and (2) prevalent new users (PNU) (who had previously used at least one GLD of the monitored drug classes, but not the inception drug). Multivariate regression explored factors associated with a meaningful change in HRQoL. RESULTS: 1303 patients. Over 26weeks, a mean positive change in the EQ-5D scores, were observed. No differences between INU and PNU were found. Participants with worse health conditions (e.g. presence and number of chronic diseases, obese) at baseline were more likely to experience larger improvements in HRQoL. CONCLUSIONS: Over 26-weeks, T2DM patients starting with, or switching to new GLD maintained or modestly increased their HRQoL.
Keywords:
Clinical pharmacology; Cohort studies; Diabetes mellitus; Quality of life; Surveys and questionnaires; Therapeutics; Type 2; Type 2/drug therapy
Authors: Kevin A Matlock; Melanie Broadley; Christel Hendrieckx; Mark Clowes; Anthea Sutton; Simon R Heller; Bastiaan E de Galan; Frans Pouwer; Jane Speight Journal: Diabet Med Date: 2021-10-07 Impact factor: 4.213
Authors: Esteban Jódar; Marie Michelsen; William Polonsky; Rosangela Réa; Anna Sandberg; Tina Vilsbøll; Mark Warren; Signe Harring; Uwe Ziegler; Stephen Bain Journal: Diabetes Obes Metab Date: 2020-04-27 Impact factor: 6.577